Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen

Pharmacogenomics and Personalized Medicine

Volumn 6, Issue 1, 2013, Pages 93-98

  Sensorn, Insee ^a   Sirachainan, Ekaphop ^b   Chamnanphon, Montri ^b   Pasomsub, Ekawat ^b   Trachu, Narumol ^b   Supavilai, Porntip ^a   Sukasem, Chonlaphat ^b   Pinthong, Darawan ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Breast cancer; CYP3A4 5; Disease free survival; Drug transporters; Pharmacogenetics; Tamoxifen

Indexed keywords

ALANINE; CYSTEINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLYCINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; TAMOXIFEN; THREONINE;

ABCB1 GENE; ABCC2 GENE; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; DISEASE FREE SURVIVAL; DRUG EFFECT; EARLY CANCER; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MARKER GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; THAILAND; TREATMENT DURATION; TREATMENT OUTCOME; WILD TYPE;

EID: 84883228374     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S44006     Document Type: Article

References (42)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
2. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310(3):1062-1075.
3. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576-586.
4. Goetz MP, Schaid DJ, Wickerham DL, etal. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res. 2011;17(21):6944-6951.
5. Rae JM, Drury S, Hayes DF, etal; ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452-460.
6. Regan MM, Leyland-Jones B, Bouzyk M, etal; Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441-451.
7. Brooks JD, Teraoka SN, Malone KE, etal; WECARE Study Collaborative Group, Bernstein JL, Figueiredo JC. Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. Int J Mol Epidemiol Genet. 2013;4(1):35-48.
8. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos. 1993;21(4):645-656.
9. Iusuf D, Teunissen SF, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen, and restricts their brain penetration. J Pharmacol Exp Ther. 2011;337(3):710-717.
10. Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer. 2007;14(2):293-303.
11. Dai D, Tang J, Rose R, etal. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299(3):825-831.
12. Hustert E, Haberl M, Burk O, etal. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11(9): 773-779.
13. Hesselink DA, van Schaik RH, van der Heiden IP, etal. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74(3):245-254.
14. Haenisch S, Zimmermann U, Dazert E, etal. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 2007;7(1):56-65.
15. Kimchi-Sarfaty C, Oh JM, Kim IW, etal. A "silent" polymorphism in the MDR1gene changes substrate specificity. Science. 2007;315(5811): 525-528.
16. Choi JH, Ahn BM, Yi J, etal. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics. 2007;17(6):403-415.
17. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 2011;11(1):25-34.
18. Schroth W, Hamann U, Fasching PA, etal. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res. 2010;16(17):4468-4477.
19. Madlensky L, Natarajan L, Tchu S, etal. Tamoxifen metabolite concentrations, CYP2D6genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89(5):718-725.
20. Xu Y, Sun Y, Yao L, etal. Association between CYP2D6 *10genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008;19(8):1423-1429.
21. Kiyotani K, Mushiroda T, Imamura CK, etal. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010;28(8): 1287-1293.
22. Park HS, Choi JY, Lee MJ, etal. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J Korean Med Sci. 2011;26(8):1007-1013.
23. Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y. No association between CYP2D6*10genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol. 2009;39(10):651-656.
24. Sukasem C, Sirachainan E, Chamnanphon M, etal. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac J Cancer Prev. 2012;13(9):4549-4553.
25. Chamnanphon M, Pechatanan K, Sirachainan E, et al. Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmgenomics Pers Med. 2013;6:37-48.
26. Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009;115(5):952-961.
27. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25(33):5187-5193.
28. Zhou Q, Yu X, Shu C, et al. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet. 2011;56(6):415-422.
29. Supanya D, Tassaneeyakul W, Sirivongs D, et al. Prevalence of CYP3A5 polymorphism in a Thai population. Thai Journal of Pharmacology. 2009;31(1):95-97.
30. Lim JSL, Chen XA, Singh O, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71(5):737-750.
31. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30-39.
32. Murdter TE, Schroth W, Bacchus-Gerybadze L, et al; German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89(5):708-717.
33. Goetz M, Rae J, Suman V, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312-9318.
34. Tucker AN, Tkaczuk KA, Lewis LM, Tomic D, Lim CK, Flaws JA. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005;217(1): 61-72.
35. Gjerde J, Geisler J, Lundgren S, etal. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 2010;10(1):313.
36. Mugundu GM, Sallans L, Guo Y, Shaughnessy EA, Desai PB. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes. Drug Metab Dispos. 2012;40(2):389-396.
37. Rooney PH, Telfer C, McFadyen MC, Melvin WT, Murray GI. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets. 2004;4(3):257-265.
38. Murray GI, Patimalla S, Stewart KN, Miller ID, Heys SD. Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 2010;57(2):202-211.
39. Baldissera VD, de Mattos AA, Coral GP, et al. Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Ann Hepatol. 2012;11(6):899-906.
40. Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 2003;22(5):1117-1121.
41. Chang H, Rha SY, Jeung H-C, et al. Association of the ABCB1 gene polymorphisms 2677G. T/A and 3435C. T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2009;20(2):272-277.
42. Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62(17):4955-4962.